Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Compass Pathways’ latest disclosures isn’t easy. Each 10-K weaves FDA feedback, psilocybin chemistry, and multi-year cash-runway tables into dense blocks of text. Add surprise 8-K releases about trial milestones and Form 4 trades by scientific founders, and you’re soon juggling dozens of documents. Investors searching for “Compass Pathways SEC filings explained simply” or “Compass Pathways 8-K material events explained” want answers, not page counts.
Stock Titan delivers that clarity. Our AI ingests every Compass Pathways quarterly earnings report 10-Q filing within minutes of hitting EDGAR, then highlights R&D spend trends and patient-response data. You receive real-time alerts when Compass Pathways Form 4 insider transactions real-time appear, and our dashboards link each trade to clinical news. Need a quick brief? Choose any filing type below—our summaries turn biotech jargon into plain English so you can focus on decisions, not deciphering.
- Compass Pathways annual report 10-K simplified
- Compass Pathways insider trading Form 4 transactions
- Compass Pathways proxy statement executive compensation
- Compass Pathways earnings report filing analysis
With those insights, professionals track how COMP360 trial costs flow through the income statement, compare cash burn to milestone payments, and monitor Compass Pathways executive stock transactions Form 4 for signals of confidence. Whether you’re modeling dilution risk or understanding Compass Pathways SEC documents with AI, our platform keeps every disclosure organized, searchable, and actionable.
COMPASS Pathways filed its Q3 2025 10‑Q, reporting a net loss of $137.7 million for the quarter. The loss was primarily driven by a $101.3 million fair value change of warrant liabilities, a non‑cash item tied to January 2025 financing warrants.
Operating expenses were $40.5 million, including $27.3 million in research and development and $13.2 million in general and administrative. Cash and cash equivalents were $185.9 million as of September 30, 2025. Shareholders’ equity was $37.6 million, reflecting $165.6 million of warrant liabilities on the balance sheet.
The company reported that its first Phase 3 TRD trial (COMP005) met its primary endpoint, and it plans to submit a proposal for rolling NDA submission to the FDA. It expects to disclose additional Phase 3 efficacy and safety data in 2026. The company states its cash is sufficient to fund operations into 2027. Ordinary shares outstanding were 96,017,044 as of October 30, 2025.
COMPASS Pathways plc furnished an update on November 4, 2025, announcing it issued a press release with financial results for the nine months ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act.
American Depositary Shares trade on the Nasdaq Global Select Market under CMPS. The report was signed by Chief Financial Officer Teri Loxam.
COMPASS Pathways plc director Jeffrey M. Jonas reported an option grant to acquire 52,000 Ordinary Shares at an exercise price of
COMPASS Pathways plc (CMPS) reported an insider ownership update. Director Jeffrey M. Jonas filed a Form 3, the initial statement of beneficial ownership, with an event date of 10/29/2025. The filing states that no securities are beneficially owned. The document was signed by Meredith Prithviraj under a power of attorney for Jeffrey M. Jonas, referencing Exhibit 24.
COMPASS Pathways (CMPS)Jeff Jonas, M.D. to its Board as a Class II director, effective October 29, 2025. He will serve on the audit and risk committee and the scientific committee. Upon joining, he will receive an option to purchase 52,000 ordinary shares (or an equivalent number of ADSs) with an exercise price set at the ADS closing price on the grant date, vesting in 36 equal monthly installments over three years.
Dr. Jonas brings leadership experience from Cure Ventures, Sage Therapeutics, ABio‑X, and multiple biotech boards. He will be eligible for annual cash retainers of $40,000 for Board service, $10,000 for audit and risk committee membership, and $6,000 for scientific committee membership. As part of a planned transition, Thomas Lönngren will retire from the Board effective December 31, 2025, and his decision was not due to any disagreement with the company.
RTW Investments, LP and Roderick Wong report shared beneficial ownership of 9,474,397 ordinary shares of COMPASS Pathways plc, representing 9.99% of the outstanding shares on a fully exercised-warrant basis. The filing states the reported amount assumes exercise of warrants to purchase 1,252,468 shares but limits exercise so the holders will not exceed 9.99% ownership. Voting and dispositive power are shared; neither reporting person claims sole voting or dispositive power. The shares are held by RTW Funds and RTW Master Fund, Ltd. is identified as having the right to receive proceeds or dividends for more than 5% of the reported shares. The filing was signed by Roderick Wong as Managing Partner of RTW Investments.
COMPASS Pathways plc Schedule 13G/A reports that TCG Crossover-affiliated funds and their managing member, Chen Yu, disclose beneficial ownership of Ordinary Shares represented by ADSs issuable upon exercise of warrants. TCG Crossover I holds 964,500 ADSs (1.0% of class) and TCG Crossover II holds 2,893,500 ADSs (2.9%), for an aggregate of 3,858,000 ADSs (3.9%) attributable to Chen Yu. The warrants may be exercisable within 60 days and are subject to an Ownership Limitation that prevents exercise to the extent it would exceed 9.99% ownership. The filers disclaim group status and state holdings are not intended to influence control.
Nantahala Capital Management, LLC and two principals report beneficial ownership of 5,934,315 American Depositary Shares of COMPASS Pathways plc, representing 6.23% of the class. The reported position includes 1,754,385 ADSs that may be acquired within sixty days through exercise of warrants, and all reported shares are held with shared voting and dispositive power rather than sole control. The filing identifies Nantahala as an investment adviser and the two individuals as control persons in respect of the shares held by Nantahala. Signatures appear for the reporting persons and a compliance officer certifies the ordinary-course nature of the holdings.
Form 4 snapshot – COMPASS Pathways plc (CMPS)
On 08/01/2025 CEO & Director Kabir Nath had 6,366 ordinary shares withheld (Code F) at $4.34 to cover tax obligations tied to restricted share unit vesting. The event is not an open-market buy or sell and does not change cash position. After the transaction Nath directly owns 221,302 shares. No derivative securities were reported.
The filing is routine, reflects equity-based compensation settlement, and has no stated impact on guidance, operations, or capital structure.
FAQ
What is the current stock price of Compass Pathways Plc (CMPS)?
What is the market cap of Compass Pathways Plc (CMPS)?
